Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same […]
Related Keywords
William Blair , Cantor Fitzgerald , News Ratings For Alnylam Pharmaceuticals Daily , Alnylam Pharmaceuticals Company Profile , Earnings History For Alnylam Pharmaceuticals , Jpmorgan Chase Co , Alnylam Pharmaceuticals Inc , Alnylam Pharmaceuticals , Alnylam Pharmaceuticals Stock , Goldman Sachs Group , Get Free Report , Alnylam Pharmaceuticals Daily , Nasdaq Alny , Dalny , Medical , 02043q10 , Earnings ,
vimarsana.com © 2020. All Rights Reserved.